Business
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
PARIS, January 08, 2026--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2025, and provided business updates.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/35d867220981c1d65bc3c3c336c45747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w3a_kkf7tMLFzd6bDdGk9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/35d867220981c1d65bc3c3c336c45747","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position amounted to €2.4 million as of December 31, 2025","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successful closing of fundraising worth nearly €2.9 million on January 7, 2026","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Payments for early access treatments are expected to be received in Q1 2026","length":75,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":215,"olType":false},{"type":"text","content":"PARIS, January 08, 2026--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2025, and provided business updates.","length":389,"tagName":"p"},{"type":"text","content":"Cash Position and Outlook","length":25,"tagName":"p"},{"type":"text","content":"As of December 31, 2025, GenSight Biologics' cash and cash equivalents totaled €2.4 million, up from €0.6 million as of September 30. This increase reflects the partial funds from the €2.9 million capital increase on December 26, which were received prior to the end of the year.","length":283,"tagName":"p"},{"type":"text","content":"On January 7, 2026, the company received the remaining proceeds from the December fundraising. After repaying €0.7 million of the principal on the convertible bonds held by Heights Capital, GenSight Biologics' cash and cash equivalents totaled €2.9 million.","length":261,"tagName":"p"},{"type":"text","content":"The company has sufficient net w...